EscharEx® Phase III VALUE trial advancing as plannedExpanded NexoBrid® manufacturing facility operational;regulatory approvals expected in ...
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results